Tagged with GEN

Opinion Kamala Maddali, vice president for Biopharma Collaborations & Companion Diagnostics at Cancer Genetics, discusses what impact next generation sequencing (NGS) stands to have on cancers that affect women.   NGS technology allows for the rapid and accurate sequencing of many genes at once 2018 saw an estimated 18 million cancer…

USA As part of Women’s History Month, Chip Davis, president and CEO of the Association for Accessible Medicines highlights some of the most outstanding women that have worked in the generic pharmaceutical industry throughout history and pinpoints the women shaping today’s landscape for affordable and accessible medicines.   As we wrap…

France Jean-Marc Grognet, general manager of Genopole, France’s leading biotechnology cluster, explains the organization’s unique triangular structure with the corner points of the cluster being higher education, research, and industry. Grognet goes on to elaborate on the cluster’s extensive scientific offering and his ambitions to build a collaborative network of life…

France Jean-Louis Anspach, general manager of Teva France, elaborates on the affiliate’s transitional restructuring period as they make a turnaround effort in the face of group-wide challenges. Anspach goes on to explain what areas will be driving Teva forward while sharing his views on the French generic and biosimilar environment.  …

Egypt Ahmed Mostafa, country manager of Amgen in Egypt and Iran, explains how the affiliate has been growing by providing end-to-end solutions. He also gives his take on the Egyptian government’s prioritization of healthcare and highlights that there are still improvements needed for bringing biosimilars to Egypt.     How would…

Korea Quegen Biotech is a company focusing on manufacturing beta-glucan for use in a range of healthcare products, from hangover cures to oncology treatments. In this interview, Dr Jong Dae Lee explains the benefits of beta glucan, and how he managed to overcome the challenges in its extraction to make it…

Novartis Richard Francis, CEO of Sandoz will step down at the end of the March. The abrupt announcement will fan the flames of rumours that parent company Novartis is planning a spinoff or sale for its generics arm.   This is a multi-year journey which I cannot commit to and therefore…

China China is planning to establish a new national medical ethics committee in the wake of the “CRISPR babies” scandal.   The committee will not be limited to overseeing gene editing alone, but also cover cloning, cell therapy, xenotransplantation, mitochondrial replacement, and nanotechnology The new body, according to reports, will oversee…

HIV Hopes have been raised of a cure for AIDS after a patient in London became free of the HIV virus following a bone marrow transplant.   Although it is not a viable large-scale strategy for a cure … these new findings reaffirm our belief that there exists a proof of…

Korea Woosok Lee, CEO of Kolon Pharma, Kolon Life Science and Kolon TissueGene, offers his insights into the potential of their blockbuster product Invossa which could exceed USD five billion of revenues in the USA following its approval. Mr Lee also clarifies Korea’s position within gene therapy R&D and explains Kolon’s…

Japan Already established as one of the world’s leading markets for innovative and patented drugs, Japan is set to grow rapidly in 2019, partly as a result of a dramatic uptake in generics and biosimilars.   Japan’s pharmaceutical industry has long centred on strong innovation and patented drugs, but we are…

Top 10 The Top 10 bestselling orphan drugs in the USA in 2017. Celgene’s Revlimid (generic name lenolidamide) leads the way with sales of USD 5.4 billion, followed by Roche’s Rituxan (rituximab) with USD 4.2 billion in sales and TEVA’s Copaxone (glatiramer acetate) with USD 3.1 billion. The most expensive drug in…